Renal cell carcinoma and COVID-19 pandemia: Management strategies adapted to current practice.

Hevia, Vital; Linares-Espinós, Estefanía; Alonso-Gordoa, Teresa; Fernández-Pello, Sergio; Guerrero-Ramos, Félix; Mir, Carmen; Molina-Cerrillo, Javier; Musquera-Felip, Mireia; Rodríguez-Faba, Óscar; de Velasco, Guillermo; Gómez-Dos Santos, Victoria

The COVID-19 pandemic caused by SARS-CoV-2 virus has caused an important health impact that has affected renal cell carcinoma management, among other urology areas. The high cancellation rate of surgeries, including those related to renal cancer, will cause an inevitable healthcare overload and probably a potential negative impact on its oncological outcomes, especially in locally advanced and metastatic renal cancer. Kidney cancer scenarios are quite different depending on their stage, distinguishing mainly between low priority of localized disease or high priority of locally advanced and metastatic under active treatment. The unknown pandemic duration and possibly fluctuating prevalence of the virus are likely to force an adaptation in the management of renal cell carcinoma among urology and oncology departments, ideally individualized ona case-by-case basis within multidisciplinary units. To this end, we present algorithms and tables regarding renal cell carcinoma management adapted to the COVID-19 period and stratified according to oncological stage, which might be useful for specialists dedicated to this uro-oncology area.